
Experts detail how steroid-refractory chronic GVHD care now uses targeted therapies and personalized choices, weighing organs, side effects, and infusion logistics.
This peer exchange convenes a multidisciplinary panel to examine how refractory chronic graft-versus-host disease is treated and coordinated across care settings. The discussion establishes where the field stands today, describing the shift from a steroid-only approach toward mechanistically distinct targeted therapies and evolving goals: minimizing steroid exposure, preserving organ function, improving quality of life, and achieving durable disease control. Faculty compare the systemic and non-pharmacologic options in steroid-refractory disease across mechanism, pivotal evidence, and clinical trade-offs, addressing sequencing, tolerability-driven decisions, patient-reported outcomes, and realistic goals of therapy. The program then turns to the practical work of coordinating infusion-based care, walking through administration logistics, monitoring, and the transition from transplant center to local oncology or home infusion. Faculty stress that transitioning care is not transferring management, sharing approaches to handoff communication, telemedicine, access barriers, and caregiver burden, before a forward look at individualized treatment.

Experts detail how steroid-refractory chronic GVHD care now uses targeted therapies and personalized choices, weighing organs, side effects, and infusion logistics.

Explore 2026 options for steroid-refractory chronic GVHD: four FDA-approved agents, key trial evidence, and where ECP fits in care.

Explore 2026 steroid-refractory chronic GVHD care: four FDA-approved drugs, key trial results, and how ECP fits into real-world treatment selection.

ROCKSTAR data and real-world experience position belimumab as a convenient, well-tolerated option for steroid-refractory chronic GVHD, while ibrutinib use declines.

This segment offers a focused look at axatilimab, the first and only CSF1R-directed monoclonal antibody approved for chronic GVHD.

This segment brings the approved therapies side by side and asks what actually drives treatment selection.

This segment walks through the practical mechanics of delivering infusion-based therapy in chronic GVHD, using axatilimab as the model.

This segment addresses the discomfort of moving infusion care off the trial model, where axatilimab was delivered at academic centers.

This segment centers on a distinction faculty return to throughout: transitioning care is not transferring management.

This segment explores who owns each part of the transition and how teams keep patients safe once care moves closer to home.

This segment examines the burdens that persist even within a well-designed transition pathway.

This segment compares the practical experience of delivering therapy across the center, local oncology, and home, and considers which patients are best suited to each.

In this closing segment, faculty distill the practical philosophy that runs through the program: a center-based start with a deliberate, clearly communicated transition remains the right approach for most patients.